{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-23-000037","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2023-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.219240+00:00","generated_at":"2026-06-09T09:49:29.588845+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Edwards Q3 sales $1.48B (+12%), EPS $0.63; TAVR grows 11%; guidance reaffirmed","bullets":["Q3 revenue $1.48B (+12% reported, +11% constant currency); GAAP EPS $0.63, adjusted EPS $0.59.","TAVR sales $961M (+11%); TMTT sales $52M on PASCAL Precision adoption; Surgical $247M (+12%).","Adjusted gross margin 76.4% vs 81.0% a year ago on FX headwinds; FY2023 guidance reaffirmed (10-13% CC sales growth, adj. EPS $2.50-$2.60).","Regulatory milestones: EVOQUE CE Mark (first transfemoral tricuspid replacement), PASCAL Precision approved in Japan, SAPIEN M3 pivotal trial enrollment completed.","Free cash flow $356M; $174M share repurchased in Q3; cash & short-term investments $1.9B."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-23-000037","json":"https://secwatch.observer/filing/0001099800-23-000037.json","markdown":"https://secwatch.observer/filing/0001099800-23-000037.md","text":"https://secwatch.observer/filing/0001099800-23-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000037/0001099800-23-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000037/ew-20231025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T09:49:29.588845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b310b38618570d8845a201cfad1f3d90a38fd35","claim":"Edwards Lifesciences Corp reported the quarter ended Sept. 30, 2023 results: revenue $1.48 billion, EPS $0.63. Guidance reaffirmed.","evidence_excerpt":"25, 2023 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2023. Recent Highlights and Outlook • Q3 sales grew 12 percent to $1.48 billion; constant currency 1 sales grew 11 percent • Q3 TAVR sales grew 11 percent; constant currency sales grew 10 percent • Q3 EPS of $0.63; adjusted 1 EPS of $0.59 • Received CE Mark","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000037/0001099800-23-000037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended Sept. 30, 2023"},{"label":"Revenue","value":"$1.48 billion"},{"label":"EPS","value":"$0.63"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}